Commodore Capital’s Cymabay Therapeutics CBAY Stock Holding History

Commodore Capital’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,025,000	Closed	-$22.2M	–	33
2023 Q2	$22.2M	Hold	2,025,000	–	–	2.49%	12
2023 Q1	$17.7M	Sell	2,025,000 -3,713,500	-65%	-$29.7M	2.69%	14
2022 Q4	$36M	Hold	5,738,500	–	–	5.42%	6
2022 Q3	$20.1M	Hold	5,738,500	–	–	3.23%	11
2022 Q2	$16.9M	Hold	5,738,500	–	–	3.58%	11
2022 Q1	$17.8M	Buy	5,738,500 +318,604	+6%	+$1M	3.99%	9
2021 Q4	$18.3M	Buy	5,419,896 +1,250,000	+30%	+$4.75M	4.24%	9
2021 Q3	$15.2M	Buy	4,169,896 +640,431	+18%	+$2.52M	4.01%	10
2021 Q2	$15.4M	Buy	3,529,465 +545,952	+18%	+$2.42M	5.36%	5
2021 Q1	$13.5M	Buy	2,983,513 +1,497,406	+101%	+$8.06M	5.4%	6
2020 Q4	$8.53M	Buy	+1,486,107	New	+$11.2M	4.64%	9

Other funds holding CBAY

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Commodore Capital's CBAY Position: Q3 2023 in Review

Commodore Capital sold out of Cymabay Therapeutics (CBAY) in Q3 2023, closing a stake of 2,025,000 shares — an estimated $22.2M sold.

Commodore Capital first reported a position in CBAY in Q4 2020 and held it in 11 quarters. The position peaked at $36M in Q4 2022. 189 funds tracked by Wall St. Rank hold CBAY as of Q3 2023.

Commodore Capital reported no remaining Cymabay Therapeutics position as of Q3 2023 after selling out during the quarter.
Commodore Capital sold 2,025,000 Cymabay Therapeutics shares in Q3 2023, an estimated $22.2M.
Commodore Capital first reported a position in Cymabay Therapeutics in Q4 2020 and held it in 11 quarters.
Commodore Capital's Cymabay Therapeutics position peaked at $36M in Q4 2022.
189 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q3 2023.

Based on Commodore Capital's 13F filing for Q3 2023, filed 14 Nov 2023.